SCOPE SUMMIT 2026 – Aarti Chitale, Industry Principal, Healthcare & Lifesciences, Frost & Sullivan
Held from 2–5 February 2026 in Orlando, Florida, SCOPE Summit 2026 marked a decisive turning point for the clinical research ecosystem. What was once discussed as future potential; AI in clinical trials, connected data environments, and patient-centric execution, is now being operationalized at scale.
With more than 4,000 attendees, 630+ speakers, and over 300 exhibitors, SCOPE has long been a bellwether for clinical innovation. This year, however, the message was unmistakable: AI adoption in clinical research has matured and digital protocols are now the backbone enabling it.
Some of the leading attendees included major pharmaceutical organizations such as Bayer, Bristol Myers Squibb, AbbVie, and Pfizer, alongside prominent Contract Research Organizations (CROs) including Thermo Fisher Scientific (PPD), PSI CRO, MD Group, Syneos Health, Ergomed, IQVIA, Veristat, Paradigm Clinical Research, Rovia Clinical Research, and Kapadi, among others.
The event also witnessed strong participation from leading technology vendors and eClinical solution providers including Medidata, Advarra, Oracle, Saama Technologies, Concert AI as well as emerging players such as Phesi, Paradigm Health, and VIDA Diagnostics.
What made SCOPE 2026 stand out was not only the scale of participation but the shift in tone. The industry has moved beyond conceptual discussions of AI, data integration, and patient-centricity. Execution is finally happening.
AI in Clinical Trials: From Proof of Concept to Purposeful Execution
One of the most prominent themes across sessions and exhibit halls was clear: AI has moved beyond pilot programs and proof-of-concept discussions. The industry is now deploying AI across the full drug development lifecycle.
At SCOPE Summit 2026, the conversation shifted from:
“Can AI work in clinical trials?”
to
“How do we scale AI responsibly and integrate it into core workflows?”
Sponsors and CROs are actively leveraging AI in clinical trials to:
- Enhance predictive site selection
- Improve patient recruitment and engagement
- Monitor electronic Clinical Outcome Assessment (eCOA) data more efficiently
- Reduce manual oversight burden
- Detect operational risks earlier
The emergence of agentic AI in clinical research; systems capable of autonomously managing multi-step workflows, reflects a significant structural shift. AI is no longer an analytical add-on; it is becoming embedded into trial execution models.
However, the key insight from SCOPE 2026 was this: AI is only as effective as the digital protocol infrastructure supporting it.
Digital Protocols as the Foundation for AI-Enabled Trials
As AI adoption matures, legacy systems such as traditional Electronic Data Capture systems (EDCs), Electronic Health Records (EHRs) integrations, and rigid eSource frameworks are revealing structural limitations. Technology silos, workflow misalignment, and fragmented data environments continue to challenge seamless deployment.
The era of one-size-fits-all clinical technology is ending.
Modern clinical trial digital transformation requires:
- Modular, interoperable systems
- Flexible data capture frameworks
- Device-agnostic workflows
- Real-time protocol adaptability
- Connected clinical data ecosystems
At SCOPE Summit 2026, leaders emphasized that digital protocols must evolve from static documentation to dynamic, executable frameworks capable of integrating AI-driven insights directly into operations.
This evolution is redefining how protocols are designed, monitored, and optimized throughout a study’s lifecycle.
Patient-centric Clinical Trials: From Philosophy to Operational Reality
Another defining shift at SCOPE 2026 was the operationalization of patient-centric clinical trials.
Rather than treating patient centricity as a high-level objective, sponsors are now embedding it into execution strategies by:
- Engaging patients and investigative sites earlier
- Designing protocols that reduce participation burden
- Enabling offline and decentralized data capture
- Improving inclusion and representation
- Aligning workflow design with real-world patient behavior
AI and connected clinical data systems are playing a crucial role in enabling this transformation, particularly in oncology and complex therapeutic areas where dropout risk and enrolment challenges are significant.
The integration of real-world data into protocol design is allowing for smarter feasibility modeling, more realistic recruitment forecasting, and improved retention strategies.
Connected Clinical Data Across the Development Value Chain
One of the strongest themes emerging from SCOPE Summit 2026 was the need for connected clinical data across the entire development value chain.
Clinical protocols, operational metrics, site logistics, real-world evidence, and patient-reported outcomes can no longer operate in isolation.
AI-driven orchestration now enables:
- Predictive site identification
- Risk-based monitoring strategies
- Real-time eCOA oversight
- Workflow automation
- Earlier detection of compliance and operational risks
When digital protocols, AI systems, and connected data environments operate cohesively, organizations can reduce execution risks, accelerate timelines, and improve study quality.
At SDC Clinical, this philosophy underpins the development of solutions such as SDC Insights 2.0 and SDC Sidekick AI, which are designed to enable risk-based monitoring, predictive analytics, and regulatory-aligned digital oversight within AI-ready trial ecosystems.
Rather than layering AI onto outdated systems, the focus is on architecting infrastructure that supports scalable, compliant, and patient-centric execution.
The Future of Clinical Trial Digital Transformation
SCOPE Summit 2026 underscored a pivotal industry inflection point.
AI in clinical trials is no longer experimental. Patient-centric design is no longer aspirational. Digital transformation is no longer optional.
The next phase of innovation will be defined by organizations that:
- Build connected clinical data ecosystems
- Adopt modular and interoperable technologies
- Design digital protocols ready for AI integration
- Prioritize operational flexibility
- Embed patient-centricity into execution models
The industry is moving toward a future defined by smarter workflows, reduced site burden, adaptive protocol design, and AI-enabled decision intelligence.
SCOPE 2026 made one thing clear: Purposeful AI, powered by sound digital protocols and connected data, is now the foundation of modern clinical research.
Annexure: Industry Growth Opportunities Reinforcing the SCOPE 2026 Vision
The strategic opportunities highlighted at SCOPE Summit 2026 closely align with Frost & Sullivan’s analyses across clinical outsourcing and early-stage drug development transformation. The following analyses provide deeper actionable intelligence and growth opportunities shaping AI-enabled, digitally integrated clinical ecosystems.
- Pharmaceutical Clinical Contract Peripheral Services, Global
- Growth Opportunities in Drug Discovery and Early Development Outsourcing Services
To explore the evolving clinical research landscape in greater depth, connect with our experts now.
